Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia (ARVC/D) is a genetically driven cardiomyopathy characterized by fibrofatty replacement of myocardial tissue, arrhythmias, and increased risk of sudden cardiac death (SCD). Advances in the understanding of its genetic basis, diagnostic modalities, and therapeutic approaches have reshaped its clinical management. This review synthesizes recent studies, particularly from 2023, focusing on genetics, imaging, risk stratification, treatment modalities, and lifestyle recommendations. Emerging tools such as artificial intelligence (AI) are also highlighted for their transformative potential in ARVC/D care.